Zobrazeno 1 - 10
of 459
pro vyhledávání: ''
Autor:
Hong Luo, Yi Hu, Patricia Keegan, Hongqian Guo, Ji-Yan Liu, Haige Chen, Sheng Yao, Weifeng Wang, Jun Guo, Fangjian Zhou, Xudong Yao, Benkang Shi, Zhigang Ji, Hui Feng, Xinan Sheng, Zhisong He, Bin Hu, Ziling Liu, Jin Wu, Xin Yao, Jinhai Fan, Yiran Huang
Publikováno v:
Clinical Cancer Research. 28:489-497
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety, efficacy
Autor:
Joanne Xiu, Michael J. Pishvaian, Ari M. Vanderwalde, Jia Zeng, Yasmine Baca, Sunnie S. Kim, John L. Marshall, W. Michael Korn, Anthony F. Shields, Axel Grothey, Heinz-Josef Lenz, Philip A. Philip, Mohamed E. Salem, Jimmy J. Hwang, Richard M. Goldberg, Michael Cerniglia
Publikováno v:
Mol Cancer Ther
The prevalence of homologous recombination–DNA damage response (HR-DDR) genetic alterations is of therapeutic interest in gastroesophageal cancers. This study is a comprehensive assessment of HR-DDR mutation prevalence across gastroesophageal adeno
Autor:
Qinghua Han, Lindsey A. Barner, Lawrence D. True, Chenyi Mao, Andrew Janowczyk, Pingfu Fu, Robert Serafin, Nicholas P. Reder, Anant Madabhushi, Jonathan T. C. Liu, Can Fahrettin Koyuncu, Patrick Leo, Sarah Hawley, Weisi Xie, Hongyi Huang, Jonathan L. Wright, Gan Gao, Adam K. Glaser, Soyoung Kang, Kevin Bishop, Nadia Postupna, C. Dirk Keene, Joshua C. Vaughan
Publikováno v:
Cancer Res
Prostate cancer treatment planning is largely dependent upon examination of core-needle biopsies. The microscopic architecture of the prostate glands forms the basis for prognostic grading by pathologists. Interpretation of these convoluted three-dim
Autor:
Eva Karamitopoulou, Aurélie Pahud de Mortanges, Aurel Perren, Beat Gloor, Andreas Andreou, Marianne Tinguely
Publikováno v:
Cancer Immunology Research. 9:1439-1450
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and immunoarchitectural features by automated morphometric analysis using multiplex immunofluor
Autor:
Michael Fulkerson, Jeffrey A. Cadeddu, Sydney Haldeman, Roy Elias, Qurratulain Yousuf, Qing Yuan, Vitaly Margulis, Alana Christie, Ananth J. Madhuranthakam, Robert C. Sibley, DK Dwivedi, James Brugarolas, Payal Kapur, Asghar Hajibeigi, Ze Zhang, Junyu Guo, Aditya Bagrodia, Matthew A. Lewis, Yin Xi, Tiffani McKenzie, Allison Joyce, Hollis Notgrass, Ivan Pedrosa, Tao Wang, Durga Udayakumar, Alberto Diaz de Leon, Renée M. McKay
Publikováno v:
Clin Cancer Res
Purpose: Intratumoral heterogeneity (ITH) challenges the molecular characterization of clear cell renal cell carcinoma (ccRCC) and is a confounding factor for therapy selection. Most approaches to evaluate ITH are limited by two-dimensional ex vivo t
Autor:
G. Iyer, Hikmat Al-Ahmadie, Erin L. Kirk, David B. Solit, Eugene J. Pietzak, William Y. Kim, Sara E. Wobker, Markia A. Smith, Kyle Roell, Matthew E. Nielsen, Bernard H. Bochner, Melissa A. Troester, Helena Furberg, Guido Dalbagni, Jeffrey S. Damrauer, Andrew F. Olshan, Katherine A. Hoadley, Halei C. Benefield, Matthew I. Milowsky, Xuezheng Sun
Publikováno v:
Clin Cancer Res
Purpose: Improved risk stratification and predictive biomarkers of treatment response are needed for non–muscle-invasive bladder cancer (NMIBC). Here we assessed the clinical utility of targeted RNA and DNA molecular profiling in NMIBC. Experimenta
Autor:
Martin H. Voss, Ed Reznik, Diego Chowell, Renzo G. DiNatale, Yasuhiro Funahashi, Pallavi Sachdev, Chung-Han Lee, Chirag Krishna, Mark Lee, Kate Weiss, Yukinori Minoshima, Darren R. Feldman, Robert J. Motzer, Doug Hoen, A. Ari Hakimi, Lynda Vuong, Samuel Murray, Luc G. T. Morris, Timothy A. Chan, Ritesh Kotecha, Junji Matsui, Maria I. Carlo, Kenichi Nomoto, Yusuke Adachi, Vladimir Makarov, Cristina Valero
Publikováno v:
Mol Cancer Res
Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have improved th
Autor:
Garry Ceccon, Philipp Lohmann, Erkan Celik, Christian Baues, Norbert Galldiks, Caroline Tscherpel, E K Bauer, Gereon R. Fink, Christoph Kabbasch, Gabriele Stoffels, Gerrit H. Gielen, Christina Schaub, Jan-Michael Werner, Johannes Weller, Ulrich Herrlinger, Karl-Josef Langen, Simone Marnitz, Niklas Schäfer
Publikováno v:
Clinical cancer research 27(13), 3704-3713 (2021). doi:10.1158/1078-0432.CCR-21-0471
Purpose: The CeTeG/NOA-09 phase III trial demonstrated a significant survival benefit of lomustine–temozolomide chemoradiation in patients with newly diagnosed glioblastoma with methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter. Fol
Autor:
Jordi Rodon, Joann Lim, Elizabeth A. Sumner, Hira Zain, Di Nguyen, Jack P. Higgins, Vivek Subbiah, Funda Meric-Bernstam, Eric T Williams, Coline Agnes Couillault, Siqing Fu, Timothy A. Yap, Kimal Rajapakshe, Aparna Hegde, Sarina Anne Piha-Paul, Shubham Pant, Michael A. Curran, Priya Bhosale, Priyamvada Jayaprakash, David S. Hong, Thomas F. Wilson, Daniel D. Karp, Ecaterina Ileana Dumbrava, Ly M. Nguyen, Cristian Coarfa
Publikováno v:
Clin Cancer Res
Purpose: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically “c
Autor:
Jennifer Bordeaux, Dustin McCurry, Arivarasan Karunamurthy, Lisa H. Butterfield, Rogerio I. Neves, Anil Pahuja, Matthew P. Holtzman, Beiru Chen, Jehovana Orozco Bender, Ahmad A. Tarhini, Yan Zang, Ju Young Kim, John M. Kirkwood, Yan Lin, Cindy Sander, Joseph J. Skitzki, IlaSri B. Summit, Marc S. Ernstoff, Christian Laing, Joseph J. Drabick, Yana G. Najjar, Huang Lin, Jennifer Tsau, Ghanashyam Sarikonda, Igor Puzanov, Hassane M. Zarour, Zeni Alfonso, Amy Rose, James F. Pingpank, Diwakar Davar
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 15
Purpose:Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therap